Akero Therapeutics, Inc. Proceeds from Common Stock Issued
Akero Therapeutics, Inc. reported Proceeds from Common Stock Issued of $1.27 billion for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-02-28
- Akero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $69.36M.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $0.00.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $1.20B.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2024 was $1.27B, a 54.59% increase from fiscal 2023.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $818.90M, a 3175.60% increase from fiscal 2022.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $25.00M.
- Akero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $202.55M, a 238198.82% increase from fiscal 2019.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $69.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $69.36M derived: sum of 2 quarters · filed 2025-02-28 | $69.36M derived: sum of 3 quarters · filed 2025-02-28 | $1.27B 10-K · filed 2025-02-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $1.20B 10-Q · filed 2024-11-08 | $1.20B derived: sum of 4 quarters · filed 2024-11-08 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.20B 10-Q · filed 2024-08-09 | $1.20B derived: sum of 3 quarters · filed 2024-08-09 | $1.20B derived: sum of 4 quarters · filed 2024-08-09 | |
| 2024-03-31 | $1.20B 10-Q · filed 2024-05-10 | $1.20B derived: sum of 2 quarters · filed 2024-05-10 | $1.20B derived: sum of 3 quarters · filed 2024-05-10 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $818.90M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $818.90M 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $818.90M 10-Q · filed 2023-08-11 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $25.00M 10-K · filed 2023-03-17 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $25.00M 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $25.00M 10-Q · filed 2022-08-05 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $202.40M derived: sum of 2 quarters · filed 2022-02-25 | $202.55M 10-K · filed 2022-02-25 | ||
| 2020-09-30 | $202.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $202.55M 10-Q · filed 2020-11-12 | |||
| 2020-07-10 | $203.46M 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $158.00K 10-Q · filed 2020-08-12 | ||||
| 2019-12-31 | $85.00K 10-K · filed 2020-03-16 |